Aptinyx Inc (APTX) News

APTX: effective Jan. 2,2024: Company Dissolved/Final Liquidation.

FINRA will delete the symbol:

https://otce.finra.org/otce/dailyList?viewType=Deletions

APTX delisted from the Nasdaq to the OTC:

https://otce.finra.org/otce/dailyList?viewType=Additions

https://stockcharts.com/h-sc/ui?s=aptx&p=D&yr=0&mn=6&dy=0&id=p38090673899

https://www.barchart.com/stocks/quotes/aptx/technical-chart?plot=CANDLE&volume=total&data=DO&density=ML&pricesOn=1&asPctChange=0&logscale=0&indicators=ACCUM;SMA(20);SMA(50);SMA(100);SMA(200);CHKMF(20)&sym=SYSX&grid=1&height=210&studyheight=100

https://www.barchart.com/stocks/quotes/aptx/opinion

Moving again!

https://stockcharts.com/h-sc/ui?s=aptx&p=D&yr=0&mn=6&dy=0&id=p38090673899

https://www.barchart.com/stocks/quotes/aptx/technical-chart?plot=CANDLE&volume=total&data=DO&density=ML&pricesOn=1&asPctChange=0&logscale=0&indicators=ACCUM;SMA(20);SMA(50);SMA(100);SMA(200);CHKMF(20)&sym=SYSX&grid=1&height=210&studyheight=100

https://www.barchart.com/stocks/quotes/aptx/opinion

APTX.............................https://stockcharts.com/h-sc/ui?s=APTX&p=W&b=5&g=0&id=p86431144783

Looks like offerings going through Now?????????

$50m+ cash in hand so no need for any offerings any time soon. Huge gaps to the up side!

Also has huge institutional investors. Takes up two pages! See the link.

Scroll all the way down

https://whalewisdom.com/stock/aptx

This patent is for a treatment for depression which unfortunately is suffered by more and more people every year so the potential market is huge.

Link to the patent.

https://data.epo.org/publication-server/pdf-document?pn=3490992&ki=B1&cc=EP

NO SHHH... THIS SHIT IS BLOWING UP AND I AM SURPRISED...

Stocktwit blowing this shit up. Over 10mil in buys AH. HOLYSHIT...

Dude if you look at the “tape” there’s a lot of buys still coming in at high of the day after hours!

Ok shhhhhh

Shhhhh…keep it quiet til AM!!!

Lowered my bid
to 10 cents.

Good day yesterday. Any reason for it?

It's one of my favorite quotes from Warren Buffett, the world's most famous value investor: "Price is what you pay; value is what you get." Get ready to get a whole lot of value with APTX going forward. This stock/company is rich with potential!

Status of each clinical study can be found here... https://www.aptinyx.com/clinical-studies/

https://www.smarteranalyst.com/new-blurbs/aptinyx-aptx-receives-a-buy-from-h-c-wainwright/?mod=mw_quote_news

Hoping to learn more about their clinical trials in progress today after market close...
https://finance.yahoo.com/news/aptinyx-inc-host-earnings-call-201500829.html

Here's a link to the NYX-783 study in Phase II trials:
https://clinicaltrials.gov/ct2/show/NCT04044664?term=NYX-783&rank=1

Here's a link to the NYX-783 study in Phase II trials:
https://clinicaltrials.gov/ct2/show/NCT04044664?term=NYX-783&rank=1

Aptinyx is advancing a leading portfolio of novel CNS therapies - pretty exciting. Here's a link to current Phase II trials in the pipeline:
https://www.aptinyx.com/pipeline/

Aptinyx is advancing a leading portfolio of novel CNS therapies - pretty exciting. Here's a link to current Phase II trials in the pipeline:
https://www.aptinyx.com/pipeline/

* * $APTX Video Chart 10-20-2020 * *

Link to Video - click here to watch the technical chart video

APTX > Conference Call Information:

scheduled for 8:30 a.m. ET

To access the live conference call and webcast presentation, please dial (866) 939-3921 (U.S. Toll Free) or (678) 302-3550 (U.S. Toll) and refer to conference ID 49992933. A live audio and webcast presentation will be available on the Investors & Media section of Aptinyx's website at https://ir.aptinyx.com. A replay of the webcast will be archived on Aptinyx's website for 30 days following the event.

New price targets, possibly above $10.00 in the forecast.

Aptinyx started at outperform with $7 stock price target at Wedbush
8:40 am ET September 12, 2019 (MarketWatch)
Share
Print
(END) Dow Jones Newswires

bam too da moon

* * $APTX Video Chart 01-17-2020 * *

Link to Video - click here to watch the technical chart video

Aptinyx started at outperform with $7 stock price target at Wedbush
8:40 am ET September 12, 2019 (MarketWatch)
Share
Print
(END) Dow Jones Newswires

September 12, 2019 08:40 ET (12:40 GMT)

Copyright (c) 2019 Dow Jones & Company, Inc.

APTX > Aptinyx Inc. is a clinical-stage biopharmaceutical company. The Company discovers and develops therapies for disorders of the brain and nervous system. The Company has a platform for discovering compounds that work through a mechanism, which includes modulation of the N-methyl-D-aspartate (NMDA) receptor to develop pathways involved with nerve cell communication. The Company's compounds are effective on disease models including, depression, neuropathic pain, migraine, traumatic brain injury and age-induced learning impairment. The Company's compounds facilitate receptor activation without over-activating the receptor. The Company’s lead product candidate is NYX-2925, a treatment for the painful diabetic peripheral neuropathy. It is also developing NYX-783 for the treatment of post-traumatic stress disorder and NYX-458 for Parkinson’s disease cognitive impairment. The Company in partnership with Allergan plc, develops AGN-241751 for major depressive disorder indications.